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Regulation of Renal Fatty Acid and Cholesterol
Metabolism, Inﬂammation, and Fibrosis in Akita and
OVE26 Mice With Type 1 Diabetes
Gregory Proctor, Tao Jiang, Mieko Iwahashi, Zhuowei Wang, Jinping Li, and Moshe Levi
In Akita and OVE26 mice, two genetic models of type 1
diabetes, diabetic nephropathy is characterized by mesan-
gial expansion and loss of podocytes, resulting in glomer-
ulosclerosis and proteinuria, and is associated with
increased expression of proﬁbrotic growth factors, proin-
ﬂammatory cytokines, and increased oxidative stress. We
have also found signiﬁcant increases in renal triglyceride
and cholesterol content. The increase in renal triglyceride
content is associated with 1) increased expression of sterol
regulatory element–binding protein (SREBP)-1c and car-
bohydrate response element–binding protein (ChREBP),
which collectively results in increased fatty acid synthesis,
2) decreased expression of peroxisome proliferator–acti-
vated receptor (PPAR)- and -, which results in decreased
fatty acid oxidation, and 3) decreased expression of farne-
soid X receptor (FXR) and small heterodimer partner
(SHP). The increase in cholesterol content is associated
with 1) increased expression of SREBP-2 and 3-hydroxy-3-
methylglutaryl (HMG)-CoA reductase, which results in
increased cholesterol synthesis, and 2) decreased expres-
sion of liver X receptor (LXR)-, LXR-, and ATP-binding
cassette transporter-1, which results in decreased choles-
terol efﬂux. Our results indicate that in type 1 diabetes,
there is altered renal lipid metabolism favoring net accu-
mulation of triglycerides and cholesterol, which are driven
by increases in SREBP-1, ChREBP, and SREBP-2 and de-
creases in FXR, LXR-, and LXR-, which may also play a
role in the increased expression of proﬁbrotic growth
hormones, proinﬂammatory cytokines, and oxidative
stress. Diabetes 55:2502–2509, 2006
T
here is growing evidence that abnormal lipid
metabolism and renal accumulation of lipids
play a role in the pathogenesis of diabetic ne-
phropathy. Virchow (1) ﬁrst suggested the asso-
ciation between lipids and renal disease in 1858 when he
described successive stages of fatty metamorphosis and
fatty detritus in the renal epithelium in Bright’s disease. In
their classic 1936 article describing the pathological sign
of nodular sclerosis, Kimmelstiel and Wilson (2) also
demonstrated the presence of lipid deposits in the kidneys
of diabetic patients, and they suggested that these lipids
play an important role in the pathogenesis of renal disease.
Since then, several investigators have shown the accumu-
lation of lipids in the kidneys of diabetic humans and
experimental animals (3,4) and have proposed that lipids
may play an important role in the pathogenesis of diabetic
kidney disease.
In studies in our laboratory in the streptozotocin-in-
duced model of type 1 diabetes in the rat, we have found
increased renal expression of the transcriptional factor
sterol regulatory element–binding protein (SREBP)-1,
which results in increased synthesis and accumulation of
triglyceride and correlates with manifestations of obesity
and diabetes-related renal sclerosis and proteinuria (5).
Whether the accumulation of lipids per se mediate
diabetic renal disease is demonstrated in SREBP-1a trans-
genic mice that overexpress SREBP-1a in the kidney. In
the absence of hyperglycemia or dyslipidemia, increased
expression of SREBP-1a in the kidney results in lipid
accumulation and increased expression of transforming
growth factor (TGF)-, plasminogen activator inhibitor
(PAI)-1, and vascular endothelial growth factor (VEGF),
which mediate renal hypertrophy, accumulation of extra-
cellular matrix proteins, and mesangial expansion, result-
ing in glomerulosclerosis and proteinuria (5). In contrast,
in SREBP-1c knockout mice, the effects of a high–satu-
rated fat diet on increased renal expression of TGF-,
PAI-1, and VEGF, as well as the extracellular matrix
proteins type IV collagen and ﬁbronectin, are prevented
(6). These studies imply that alterations in renal lipid
metabolism mediated by SREBPs play an important role in
the pathogenesis and progression of renal disease in type
1 diabetes, as well as in obesity and insulin resistance.
Recently, the carbohydrate response element–binding
protein (ChREBP) has also been shown to play an impor-
tant role in regulation of fatty acid synthesis in the liver
(7–9). ChREBP may work in concert with SREBP-1c to
mediate fatty acid and triglyceride in the liver (7–9).
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In addition, another nuclear receptor, the farnesoid X
receptor (FXR), has also been shown to have an important
role in the regulation of fatty acid metabolism in the liver
by inhibiting SREBP-1 and ChREBP, while inducing per-
oxisome proliferator–activated receptor- (PPAR-) (10,
11). However, the regulation of FXR in the kidney has not
been determined.
In models of obesity and insulin resistance, as well as
type 2 diabetes, we have found that in addition to triglyc-
eride, cholesterol also accumulates in the kidney (6,12).
SREBP-2 is the master transcriptional regulator of choles-
terol synthesis by way of inducing enzymes that mediate
cholesterol synthesis, including cholesterol 3-hydroxy-3-
methylglutaryl (HMG)-CoA reductase (13,14), whereas the
liver X receptor (LXR) modulates cholesterol efﬂux via
inducing ATP-binding cassette transporter (ABCA)-1 (11).
The regulation of SREBP-2 and LXR in the kidney of
animals with type 1 diabetes, however, has not been
determined.
The purpose of our study was to determine the potential
role of alterations in renal triglyceride and cholesterol
metabolism in two recently described genetic models of
type 1 diabetes in mice: the Ins2
Akita mice on the C57BL/6
background (15,16) and the OVE26 mice on the FVB
background (17). Our objective was also to determine the
potential roles of the nuclear receptors that regulate fatty
acid metabolism (SREBP-1, ChREBP, PPAR-, and FXR)
and cholesterol metabolism (SREBP-2 and LXR) in regu-
lation of renal lipid metabolism and diabetic nephropathy.
Our results indicate that in type 1 diabetes, altered renal
lipid metabolism favors net accumulation of triglyceride
and cholesterol, which are driven by 1) increases in the
expression and activity of SREBP-1, ChREBP, and
SREBP-2 and 2) decreases in the expression and activity
of the nuclear receptors FXR, LXR-, and LXR-, which
may also play a role in the increased expression of
proﬁbrotic growth hormones, proinﬂammatory cytokines,
and oxidative stress.
RESEARCH DESIGN AND METHODS
Male C57BL/6-Ins2
Akita (Akita) mice in the C57BL/6 background and C57BL/6
control mice were obtained from The Jackson Laboratories (Bar Harbor, ME).
Ins2
Akita is a model of type 1 diabetes. The Akita spontaneous mutation is an
autosomal dominant mutation in the insulin II gene (Ins2) (15,16). This
missense mutation results in an amino acid substitution (cysteine 96 to
tyrosine), which corresponds to the seventh amino acid position of the insulin
II A chain. The mice were maintained on a 12-h light/dark cycle and fed
standard mouse chow (Mouse Chow 5015; Ralston Purina, St. Louis, MO) ad
libitum for 3 months until they were killed. The animal studies and the
protocols were approved by the institutional review boards at the Denver
Veterans Medical Center and the University of Colorado Health Sciences
Center.
At the end of the 3 months, spot urine samples were obtained so that
albumin and creatinine levels could be measured. In one group of animals
(n  8 in each experimental group), after anesthesia (intraperitoneal injection
of pentobarbital; Abbott Laboratories, Chicago, IL), blood was drawn from the
inferior vena cava, and then the kidneys were removed and processed for
biochemical studies that included 1) RNA extraction and real-time quantita-
tive PCR, 2) isolation of nuclei and microsomes and Western blotting, 3)
measurement of stearoyl CoA desaturase-1 (SCD-1) enzyme activity, and 4)
lipid extraction and lipid composition analysis. In another group of animals
(n  4 in each experimental group), after anesthesia, the kidneys were ﬁxed
via in vivo perfusion ﬁxation and the kidneys were processed for 1) periodic
acid Schiff (PAS) stain for renal histopathology, 2) oil red O stain for neutral
lipids, and 3) immunoﬂuorescence microscopy for extracellular matrix pro-
teins (5,6,12,18,19).
Parallel studies were also performed in the OVE26 model of type 1
diabetes. These transgenic mice express a chicken calmodulin minigene
controlled by the rat insulin II promoter and develop hyperglycemia within
24 h of age because of decreased pancreatic insulin (17). Male OVE26 mice on
the FVB background and control FVB mice were obtained from Dr. Paul
Epstein at the University of Louisville, Kentucky, and from The Jackson
Laboratories.
Measurement of urine albumin and creatinine. Urine albumin concentra-
tion was determined by competitive enzyme-linked immunosorbent assay
using an Albuwell M kit (Exocell, Philadelphia, PA). Urine creatinine concen-
tration was determined by Jaffe’s reaction of alkaline picrate with creatinine
using a Creatinine Companion kit (Exocell). Results were expressed as the
urine albumin-to-creatinine ratio (micrograms per milligram) (5,6,12,18,19).
Total RNA extraction and real-time PCR. Total RNA was extracted
according to the Trizol protocol (Invitrogen Life Technologies, Carlsbad, CA).
Total RNA (2 g) was subjected to DNase digestion followed by cDNA
synthesis using the iScript cDNA Synthesis kit (Bio-Rad, Richmond, CA). We
used iQSYBR Green Supermix (Bio-Rad) for real-time PCR according to the
manufacturer’s instructions. Cyclophilin was used as internal control, and the
amount of RNA was calculated by the comparative CT method. All data were
calculated from duplicate reactions, as we have previously described
(5,6,12,18,19). Primers used are listed in Table 1.
Nuclei and microsome isolation. Kidneys were homogenized at 4°C in a
buffer (20 mmol/l Tris-Cl, pH 7.4, 75 mmol/l NaCl, 2 mmol/l EGTA, 2 mmol/l
EDTA, 1 mmol/l Na3VO4, and 1 mmol/l dithiothreitol), supplemented with a
protease inhibitor cocktail that consisted of 104 mmol/l AEBSF, 0.08 mmol/l
aprotinin, 2 mmol/l leupeptin, 4 mmol/l bestatin, 1.5 mmol/l pepstatin A, and
1.4 mmol/l E-64 (Sigma-Aldrich, St. Louis, MO). Nuclear extracts and micro-
somes were prepared as we have previously described (5,6,12,18,19).
Protein electrophoresis and Western blotting of nuclear extracts and
microsomes. Equal amounts of protein samples were subjected to SDS-PAGE
(10% wt/vol), and they were then transferred to nitrocellulose membranes.
After blockage with 5% fat-free milk powder with 1% Triton X-100 in
Tris-buffered saline (20 mmol/l Tris-Cl, 150 mmol/l NaCl, pH 7.4), the blots
were incubated with antibodies against SREBP-1 (Santa Cruz Biotechnology,
Santa Cruz, CA; 1:1,000), SREBP-2 (Santa Cruz Biotechnology; 1:1,000), and
SCD-1 (Santa Cruz Biotechnology; 1:1,000). The SREBP-1 antibody recognizes
both SREBP-1a and -1c. Corresponding secondary antibodies were visualized
using enhanced chemiluminescence (Pierce, Bradford, IL). The signals were
quantiﬁed with a Phosphor Imager with chemiluminescence detector and the
accompanying densitometry software (Bio-Rad).
Measurement of SCD enzyme activity. SCD enzyme activity was measured
in microsomes prepared from individual kidney cortex extracts by determin-
ing the conversion of [1-
14C] stearoyl-CoA to [1-
14C] oleate (20).
Lipid extraction and measurement of lipid composition. Lipids from the
renal cortex were extracted by the method of Bligh and Dyer, as we have
previously described (5,6,12,18,19). Triglyceride and cholesterol content was
measured using kits from Sigma according to instructions of the manufacturer.
Perfusion ﬁxation of mouse kidney. Mice were anesthetized and perfused
at a pressure of 180 mmHg through the abdominal aorta, as previously
described (5,6,12,18,19).
PAS staining, oil red O staining, and immunoﬂuorescence microscopy.
Parafﬁn sections were stained for PAS. Frozen sections were used for oil red
O staining to determine the renal accumulation of neutral fats (5,6,12,18,19).
The stained kidney sections were imaged with an Olympus microscope.
Immunoﬂuorescence microscopy for type IV collagen and ﬁbronectin were
performed as previously described (5,6,12,18,19). The kidney sections were
then imaged with a laser scanning confocal microscope (Zeiss LSM 510).
Statistical analysis. SPSS 11.0 for Windows was used for statistical analysis.
The results were expressed as the means  SE. The statistical signiﬁcance of
differences was assessed by unpaired t test.
RESULTS
Ins2
Akita mice
Mesangial expansion, podocyte injury, glomerulo-
sclerosis, tubulointerstitial ﬁbrosis, and protein-
uria. In Ins2
Akita mice, PAS staining clearly reveals
mesangial expansion, increased matrix protein accumula-
tion, and tubulointerstitial ﬁbrosis when compared with
age- and sex-matched control mice (Fig. 1A). Immunoﬂu-
orescence microscopy with anti-ﬁbronectin (results not
shown) and anti-type IV collagen (Fig. 1B) antibodies
indicates increased intensity of immunoﬂuorescence in
the glomeruli and tubulointerstitial cells in Ins2
Akita mice,
indicating accumulation of extracellular matrix proteins.
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Akita mice have signiﬁcant decreases in the mRNA
abundance of the podocyte marker proteins synaptopodin
and podocin (Table 2). These changes are associated with
a signiﬁcant increase in the urine albumin-to-creatinine
ratio in Ins2
Akita when compared with control mice (Table
2).
Increased renal expression of growth factors and
inﬂammatory cytokines. The glomerulosclerosis, tubu-
lointerstitial ﬁbrosis, and proteinuria in Ins2
Akita mice are
associated with signiﬁcant increases in renal cortical
mRNA abundance of 1) ﬁbrosis-inducing growth factors
TGF- and PAI-1, 2) glomerular permeability–inducing
growth factor VEGF, and 3) proinﬂammatory cytokine
tumor necrosis factor (TNF)- (Table 2).
Increased lipid deposits in kidney. In contrast to
minimal or absent oil red O staining in the kidneys of the
control mice, there is very strong staining of oil red O in
the glomeruli of Ins2
Akita mice, which indicates accumu-
lation of neutral lipid deposits (Fig. 2A). Biochemical
analysis of lipid composition of the renal cortex indicates
that the accumulation of neutral lipid deposits corre-
sponds to signiﬁcant increases in triglyceride and choles-
terol content (Fig. 2B).
Alterations in renal expression of nuclear receptors
and genes that regulate triglyceride and cholesterol
metabolism. Ins2
Akita mice have a signiﬁcant increase in
SREBP-1 nuclear protein abundance, a nuclear receptor/
transcription factor that is a master regulator of fatty acid
and triglyceride synthesis (Table 3). To determine the
functional signiﬁcance of the increase in SREBP-1 protein,
we determined the mRNA, protein, and enzyme activity of
SCD-1, a key enzyme in regulation of fatty acid and
triglyceride synthesis. We found that Ins2
Akita mice have
signiﬁcant increases in SCD-1 mRNA, SCD-1 protein, and
SCD-1 enzyme activity (Table 3).
Interestingly, the expression of FXR, a nuclear receptor
that is an important negative regulator of SREBP-1c and
TGF-, and its major target small heterodimer partner
(SHP) were signiﬁcantly decreased in the kidneys of
Ins2
Akita mice (Table 3).
Ins2
Akita mice also have a signiﬁcant increase in
SREBP-2 nuclear protein abundance, a nuclear receptor/
transcription factor that is a master regulator of choles-
terol synthesis (Table 3). In addition, Ins2
Akita mice have a
signiﬁcant decrease in ABCA-1 mRNA abundance, a key
enzyme that mediates cholesterol efﬂux (Table 3).
Interestingly, the expression of LXR- and LXR-, nu-
clear receptors that are important positive regulators of
ABCA-1 and negative regulators of proinﬂammatory cyto-
kines, were signiﬁcantly reduced in the kidneys of
Ins2
Akita mice (Table 3).
OVE26 mice
Podocyte injury and increased accumulation of ex-
tracellular matrix proteins. Previous studies deter-
mined that OVE26 mice on the FVB genetic background
develop severe glomerulosclerosis and proteinuria (17). In
our study, we conﬁrmed these ﬁnding (results not shown),
and we have also determined that there is a marked
increase in the mRNA abundance for type IV collagen and
ﬁbronectin (Table 4), which suggests that the increased
expression and accumulation of the extracellular matrix
proteins are transcriptionally regulated. In addition, these
TABLE 1
Primers used in quantitative real-time PCR
Gene Sense Antisense
Cyclophilin TGGAGAGCACCAAGACAGACA TGCCGGAGTCGACAATGAT
ACC CCCAGCAGAATAAAGCTACTTTGG TCCTTTTGTGCAACTAGGAACGT
Fatty acid synthase CCTGGATAGCATTCCGAACCT AGCACATCTCGAAGGCTACACA
HMG-CoA reductase AGCCGAAGCAGCACATGAT CTTGTGGAATGCCTTGTGATTG
SREBP-1c GGCACTAAGTGCCCTCAACCT TGCGCAGGAGATGCTATCTCCA
SREBP-2 CAAGTCTGGCGTTCTGAGGAA ATGTTCTCCTGGCGAAGCT
Acyl-CoA oxidase GGCCAACTATGGTGGACATCA ACCAATCTGGCTGCACGAA
ABCA-1 CGTTTCCGGGAAGTGTCCTA GCTAGAGATGACAAGGAGGATGGA
ChREBP CGGGACATGTTTGATGACTATGTC ACCCGCACGCTGCACAACTGG
L-PK CTTGCTCTACCGTGAGCCTC ACCACAATCACCAGATCACC
LXR- TTGCACCCGACCCTCAGA AAGCCCGACAACAGCGCTTTGC
LXR- CGACTCCAGGACAAGAAGC TCAAGAAGACACCACCAAGG
Farnesoid X receptor CCAACCTGGGTTTCTACCC CACACAGCTCATCCCCTTT
PPAR- CTGCAGAGCAACCATCCAGAT GCCGAAGGTCCACCATTTT
PPAR- TCCAGAAGAAGAACCGCAACA GGATAGCGTTGTGCGACATG
TGF- TAGTAGACGATGGGCAGTGG TAGTAGACGATGGGCAGTGG
VEGF AACGATGAAGCCCTGGAGTG TGAGAGGTCTGGTTCCCGA
PAI-1 GGACACCCTCAGCATGTTCA TCTGATGAGTTCAGCATCCAAGAT
MCP-1 GTCCCTGTCATGCTTCTGG CATCTTGCTGGTGAATGAGTAG
TNF- AATGGCCTCCCTCTCATCAGT GCTACAGGCTTGTCACTCGAATT
IL-6 TATGAAGTTCCTCTCTGCAAGAGA TAGGGAAGGCCGTGGTT
Fibronectin AGACCATACCTGCCGAATGTAG GAGAGCTTCCTGTCCTGTAGAG
Nephrin CGA GGC ACT TCG TGA AAC GCA CTT GCT CTC CCA GGA CT
Podocin TTT GCC TTT GCC ATT TGA CA ATG CTC CCT TGT GCT CTG TTG
Synaptopodin GTG TTC ATC TGT GCC CAT TCC AGC TAG CCG AGG CCA TGT TA
Type IV collagen TACCTGCCACTACTTCGCTAAC CGGATGGTGTGCTCTGGAAG
Nox4 GTGAAGATTTGCCTGGAAGAAC GATGATTGATGACTGAGATGATGG
Phoxp22 GCACACCGCCATCCACAC CCAGCCAACCGAGTCACG
Phoxp47 CCATCATCCTTCAGACCTATCG CCGCTCTCGCTCTTCTCC
RAGE CCATCCTACCTTCTCCTG AGCGACTATTCCACCTTC
RAGE, receptor for advanced glycation end products.
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dance for the podocyte marker proteins podocin and
synaptopodin (Table 4).
Increased renal expression of inﬂammatory cyto-
kines and oxidative stress. OVE26 mice have signiﬁ-
cant increases in renal cortical mRNA abundance of 1) the
proinﬂammatory cytokines TNF- and interleukin (IL)-6
(Table 4), 2) markers of oxidative stress, including com-
ponents of the NADPH oxidase system (Nox4, p22phox,
and p47phox) (Table 4), and 3) receptor for advanced
glycation end products (Table 4).
Alterations in renal expression of nuclear receptors
and genes that regulate triglyceride and cholesterol
metabolism. OVE26 mice have signiﬁcant increases in
mRNA abundance of SREBP-1c target enzymes acetyl-CoA
carboxylase (ACC) and fatty acid synthase (FAS) (Table
5), enzymes that initiate the cascade of fatty acid synthe-
sis. In addition, there is also marked upregulation of
ChREBP and its major target enzyme, liver pyruvate
kinase (L-PK) (Table 5), which, in concert with the
SREBP-1 pathway, mediates fatty acid and triglyceride
synthesis.
The increases in SREBP-1– and ChREBP-dependent
fatty acid synthesis pathways are paralleled by marked
decreases in the expression of PPAR-, PPAR-, and their
target enzyme acyl-CoA oxidase (ACO) (Table 5), which
FIG. 1. A: PAS staining of kidney sections indicates increased mesan-
gial expansion and accumulation of matrix proteins in C57BL/6-
Ins2
Akita mice compared with control mice; immunoﬂuorescence
microscopy of kidney sections indicates increased glomerular and
tubulointerstitial staining for ﬁbronectin (B) and type IV collagen (C)
in Akita mice.
FIG. 2. A: There is a marked increase in glomerular oil red O staining
in the kidneys of Akita mice compared with control mice, which
indicates an increase in neutral lipid (cholesterol and triglycerides)
accumulation. B: There are signiﬁcant increases in triglyceride and
cholesterol content in the kidneys of Akita mice compared with control
(CON) mice.
TABLE 2
Urinary albumin excretion, podocyte, proﬁbrotic growth factor, and proinﬂammatory cytokine mRNA expression in wild-type and
Akita mice
Wild type Akita P value
Urinary albumin-to-creatinine ratio 0.3  0.1 1.8  0.1 0.01
Podocyte markers
Synaptopodin 30.2  1.0 7.1  0.8 0.01
Podocin 44.9  1.3 11.2  0.7 0.01
Proﬁbrotic growth factors
TGF- 1.9  0.1 4.1  0.2 0.05
PAI-1 0.9  0.1 6.0  0.2 0.01
Proinﬂammatory cytokines
VEGF 2.1  0.2 3.6  0.2 0.05
TNF- 1.7  0.2 4.1  0.3 0.01
Data are means  SE (n  6 mice in each group).
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fatty acid synthesis and decreased fatty acid oxidation are
paralleled by a marked decrease in FXR expression (Table
5), a nuclear receptor that has been shown in the liver to
be a negative regulator of SREBP-1 and ChREBP and a
positive regulator of PPAR-.
OVE26 mice also have a signiﬁcant increase in SREBP-2
mRNA abundance, a nuclear receptor and transcription
factor that is a master regulator of cholesterol synthesis
(Table 5) and its major target enzyme HMG-CoA reductase
(Table 5), which is a key enzyme in cholesterol synthesis.
Interestingly, the expression of LXR- and LXR-, nu-
clear receptors that are important positive regulators of
ABCA-1 and negative regulators of proinﬂammatory cyto-
kines, were signiﬁcantly reduced in the kidneys of OVE26
mice (Table 5).
DISCUSSION
Well-known changes in diabetes-related renal function and
structure include mesangial expansion and podocyte in-
jury and loss, which result in glomerulosclerosis, protein-
uria, and a decline in glomerular ﬁltration rate (21–29).
Several hormonal and metabolic factors, including proﬁ-
brotic growth factors (angiotensin II, TGF-, and VEGF),
proinﬂammatory cytokines (TNF- and IL-6), oxidative
stress, and advanced glycation end products have been
shown to modulate diabetes-related renal disease (30,31).
Renal accumulation of lipids has also been thought to play
a role in the pathogenesis of diabetic nephropathy (1–6).
Our previous study of streptozotocin-induced type 1 dia-
betes in the rat showed that increased lipid synthesis
mediated by increased activity of SREBP-1 plays an im-
portant role in the development of diabetic nephropathy
(5). Furthermore, we were able to demonstrate that in-
creased renal expression of SREBP-1a per se is the key
factor linking increased fatty acid synthesis and accumu-
lation of lipids to development of nephropathy (5).
In this study of two different genetic mouse models of
type 1 diabetes, we also demonstrate that the glomerulo-
sclerosis and proteinuria are associated with increased
triglyceride and cholesterol accumulation.
A novel ﬁnding of our study is that we demonstrate that
in addition to increased SREBP-1 activity, increased
ChREBP activity most likely plays a role in increased fatty
acid synthesis and accumulation of triglycerides. ChREBP
has previously been shown to play an important role in
triglyceride synthesis in the liver (7–9) and adipose tissue
(32). ChREBP mediates insulin-independent, glucose-stim-
ulated gene expression of multiple liver enzymes that are
responsible for converting excess carbohydrate to fatty
acids for long-term storage (7–9). This is the ﬁrst demon-
stration of increased expression of ChREBP and L-PK in
diabetic kidneys, which, along with SREBP-1c, may play
an important role in mediating increased fatty acid synthe-
sis in the kidney.
In addition to increased fatty acid synthesis induced by
coordinate upregulation of SREBP-1 and ChREBP, our
study also demonstrates that decreased fatty acid oxida-
TABLE 3
Nuclear receptor and lipid metabolism enzyme activity, protein,
and mRNA expression in wild-type and Akita mice
Wild type Akita P value
Fatty acid synthesis
SREBP-1 protein 3.0  0.2 5.4  0.2 0.01
SCD-1 mRNA 1.8  0.2 3.6  0.3 0.05
SCD-1 protein 7.2  0.1 11.6  0.3 0.05
SCD-1 activity 2.5  0.1 4.2  0.3 0.05
FXR mRNA 9.1  0.2 2.0  0.4 0.01
SHP mRNA 3.9  0.2 2.1  0.4 0.05
Cholesterol synthesis
and efﬂux
SREBP-2 protein 1.6  0.2 3.4  0.3 0.01
ABCA1 mRNA 14.8  1.0 5.8  0.9 0.01
LXR- 12.3  0.8 3.1  0.7 0.01
LXR- 12.9  0.9 2.1  0.8 0.01
Data are means  SE (n  6 mice in each group).
TABLE 4
Podocyte, extracellular matrix protein, proinﬂammatory cyto-
kine, and NADPH oxidase mRNA expression in wild-type and
OVE26 mice
Wild type OVE26 P value
Podocyte markers
Podocin 86.2  4.3 17.8  6.8 0.01
Synaptopodin 19.9  3.1 5.6  2.7 0.01
Extracellular matrix
proteins
Fibronectin 39.2  4.7 204.7  6.1 0.01
Type IV collagen 2.7  0.3 12.6  0.6 0.01
Proinﬂammatory
cytokines
TNF- 0.2  0.3 1.8  0.1 0.01
IL-6 0.8  0.4 7.2  1.0 0.01
Oxidative stress
Nox4 12.8  1.9 36.7  2.1 0.05
Phoxp22 2.4  0.4 5.9  0.5 0.05
Phoxp47 5.8  2.8 44.8  3.9 0.01
RAGE 16.8  1.8 49.7  3.7 0.05
Data are means  SE (n  5 mice in each group).
TABLE 5
Nuclear receptor and lipid metabolism enzyme mRNA expres-
sion in wild-type and OVE26 mice
Wild type OVE26 P value
Fatty acid
synthesis
SREBP-1c 3.6  0.5 7.1  0.8 0.05
ACC 3.2  0.8 7.8  0.7 0.05
FAS 2.1  0.5 4.8  0.4 0.05
ChREBP 1.4  0.3 4.2  0.4 0.01
L-PK 7.1  1.0 14.9  1.2 0.05
Fatty acid
oxidation
PPAR- 12.1  0.6 3.9  0.9 0.01
PPAR- 14.7  0.5 4.0  0.7 0.01
ACO 4.6  0.2 1.8  0.3 0.01
FXR 5.3  0.3 2.3  0.4 0.05
Cholesterol
synthesis
SREBP-2 3.9  0.6 12.7  0.9 0.01
HMG-CoA
reductase 2.1  0.3 5.1  0.4 0.05
Cholesterol
efﬂux
LXR- 6.3  0.4 3.1  0.5 0.05
LXR- 22.1  0.6 7.9  0.9 0.05
ABCA1 8.9  0.4 3.7  0.4 0.05
Data are means  SE (n  5 mice in each group).
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PPAR-, PPAR-, and ACO also may play a role in the
eventual triglyceride accumulation (33,34). Interestingly, a
recent study found accelerated diabetic nephropathy in
mice lacking PPAR- (35).
Another novel ﬁnding of our study is that we have found
decreased expression of FXR and its immediate target
(SHP) in the kidneys of the Akita and OVE26 mice. FXR is
highly expressed in liver, kidney, intestine, colon, and
adrenal glands. Similar to PPARs, FXR binds DNA as an
obligate heterodimer with the retinoid X receptor (RXR)
(10,11). The regulation of FXR in the kidney, however, has
not been determined.
In the liver, FXR has been shown to play an important
role in regulation of triglyceride metabolism by decreasing
the expression of SREBP-1 and ChREBP and increasing
the expression of PPAR- (10,11). Indeed, FXR knockout
mice have increased liver triglyceride content (36). Our
results, therefore, indicate that the decrease in FXR and its
major target, SHP, could mediate the increases in SREBP-1
and ChREBP and decreases in PPAR- and -, which result
in increased fatty acid and triglyceride synthesis and
accumulation of triglyceride in the kidney.
Recent studies indicate that FXR agonists also modulate
ﬁbrosis. In rat models of extrahepatic and intrahepatic
cholestasis, the FXR agonist GW4064 protects against
cholestatic liver damage in part by decreasing the expres-
sion of TGF- (37). In additional models of liver cirrhosis
and ﬁbrosis, treatment with the FXR agonist 6-ethyl che-
nodeoxycholic acid causes decreased expression of 1)
TGF-1, 2) tissue metalloproteinase inhibitor-1 and -2, 3)
1 (I) collagen, 4)  smooth muscle actin, and 5) increased
expression and activity of matrix metalloproteinase-2.
These effects result in resolution of hepatic ﬁbrosis (38).
Our results therefore also indicate that the decrease in
FXR and its major target (SHP) could also mediate the
increased expression of TGF- in the kidney, resulting in
podocyte loss, accumulation of extracellular matrix pro-
teins, renal ﬁbrosis, and proteinuria.
In addition to increased triglyceride content, we have
also found a signiﬁcant increase in renal cholesterol
content. The cholesterol accumulation is mediated by
SREBP-2– and HMG-CoA reductase–induced increases in
cholesterol synthesis. At the same time, we also found
evidence for a potential decrease in cholesterol efﬂux
mediated by decreased expression of ABCA-1.
An additional novel ﬁnding of this study is that in
addition to the regulation of SREBP-1, ChREBP, PPAR-,
PPAR-, FXR, and SREBP-2, we have also found signiﬁ-
cant modulation of LXR- and LXR- in the kidneys of the
Akita and OVE26 mice.
LXRs are members of the ligand-activated nuclear re-
ceptor family of transcription factors, and they function as
intracellular sensors of sterols (11,39). LXRs regulate
intestinal uptake of dietary cholesterol, cellular efﬂux of
cholesterol in peripheral tissues to HDL, and its eventual
excretion from the body via the bile. In response to
binding their sterol ligands, LXRs stimulate ABCA-1–me-
diated transport of cholesterol and phospholipids out of
the cell interior to apolipoprotein A1–containing HDL.
Hepatic expression of LXR promotes excretion of choles-
terol from the body via two processes: 1) direct transport
of cholesterol into biliary canaliculi by way of the ABC
transporter proteins ABCG5 and ABCG8 and 2) upregula-
tion of cytochrome P450 7-hydroxylase (CYP7A1), which
converts cholesterol to bile acids.
In addition to their roles in cholesterol metabolism,
LXRs exert important regulatory effects on triglyceride
metabolism. These effects are largely caused by their
coordinate regulation of SREBP-1c, the master regulator
of triglyceride and fatty acid synthesis. LXR transcrip-
tional response elements are present in the promoter of
SREBP-1c; however, the net effect on hepatic and serum
triglycerides has been variable after treatment with differ-
ent synthetic LXR agonists (40–42).
The decrease in LXR expression in the diabetic kidney
may mediate the decreased expression of ABCA-1 and
result in decreased cholesterol efﬂux. A signiﬁcant in-
crease in cholesterol accumulation in the kidney is the net
result of increased cholesterol synthesis mediated by
increased expression of SREBP-2 and HMG-CoA reductase
and decreased cholesterol efﬂux mediated by decreased
expression of LXR-, LXR-, and ABCA-1.
As modulators of inﬂammatory cytokines, LXRs may be
important in diabetic kidney disease (39). LXRs and their
ligands are negative regulators of macrophage inﬂamma-
tory gene expression. In activated macrophages, LXRs
repress expression of the proinﬂammatory genes IL-6,
IL-1, cyclooxygenase-2, granulocyte colony–stimulating
factor, inducible nitric oxide synthase, and matrix metal-
loproteinase-9, as well as the chemokines monocyte che-
moattractant protein-1 and macrophage inﬂammatory
protein-1. In our studies, we found increased expression
of TNF- and IL-6 in diabetic kidneys of OVE26 and Akita
mice, which could be mediated by decreased expression
of LXR.
Proinﬂammatory cytokines in the diabetic kidney can
also induce downregulation of LXR and FXR (43,44),
which would then modulate renal lipid metabolism and
add to the complexity of the interactions between nuclear
receptors and proinﬂammatory cytokines in the pathogen-
esis of diabetic kidney disease.
We propose that the increases in renal triglyceride and
cholesterol accumulation play an important role in the
pathogenesis of diabetic nephropathy. Three lines of evi-
dence suggest that altered lipid metabolism is associated
with diabetic and nondiabetic renal disease. First, there
are a number of genetic abnormalities of lipid metabolism
in humans and experimental animals, including Fabry’s
disease (45); lecithin cholesterol acyltransferase deﬁ-
ciency (46); type IA glycogen storage disease (von Gierke’s
disease) (47); genetic and acquired lipodystrophy (48);
ABCA-1 knockout mice (a murine model of Tangiers
disease) and familial HDL deﬁciency, with defects in
ABCA-1– and HDL-mediated reverse cholesterol transport
(49); and ApoE knockout mice (50), in which abnormali-
ties in serum and tissue lipids, including renal lipid com-
position, are associated with glomerular disease and
proteinuria. Second, increases in serum lipids have been
associated with a faster decline of renal function (51).
Third, there is increasing evidence that inhibition of cho-
lesterol synthesis by HMG-CoA reductase inhibitors (st-
atins), inhibition of triglyceride synthesis by PPAR-
agonists (ﬁbrates) (52), or a decrease in LDL achieved by
LDL apheresis (29) protect against diabetic and nondia-
betic renal disease.
In summary, our ﬁndings in Akita and OVE26 mice with
type 1 diabetes show renal lipid accumulation, glomerular
matrix expansion and sclerosis, podocyte loss, and devel-
opment of proteinuria (Fig. 3). Our lipid metabolism
pathway analysis suggests a global shift in diabetic renal
metabolism toward 1) increased fatty acid synthesis me-
G. PROCTOR AND ASSOCIATES
DIABETES, VOL. 55, SEPTEMBER 2006 2507diated by increases in SREBP-1, ACC, FAS, SCD-1,
ChREBP, and L-PK; 2) decreased fatty acid oxidation
mediated by decreases in PPAR-, PPAR-, and ACO; 3)
increased cholesterol synthesis mediated by increases in
SREBP-2 and HMG-CoA reductase; and 4) decreased cho-
lesterol efﬂux mediated by decreases in LXR-, LXR-, and
ABCA-1. We also found increased levels of the proﬁbrotic
growth factors TGF-, PAI-1, and VEGF; the proinﬂamma-
tory cytokines IL-6 and TNF-; oxidative stress; and recep-
tor for advanced glycation end products. We have
observed a pattern of reciprocal changes in renal lipid
biosynthesis and ﬁbrosis/inﬂammation/oxidative stress in
diabetic kidneys of Akita and OVE26 mice, which could be
explained mechanistically by the corresponding changes
we found in LXR and FXR expression. This parallels
similar ﬁndings in liver and macrophages by other inves-
tigators. Our ﬁndings suggest but do not prove a signiﬁcant
role for LXR and FXR in the development of the proin-
ﬂammatory, proﬁbrotic, and prolipogenic environment
characteristic of diabetic kidney disease and warrant
future investigations of synthetic agonists of FXR and LXR
for their potential roles as therapeutic agents for the
treatment of diabetic kidney disease.
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